Why do we genetically modify animals

Genetically modified animals. Despite its potential to battle disease and hunger, genetically engineered food is still controversial. Gene-edited pigs, above, have been made resistant to the PRRS virus - a deadly pig disease. Reuse this content. What is the purpose of the guidance and what did the FDA say? The FDA laid out a process for the science-based review of applications and how they would lead to an approval.

The proposed framework is similar to international guidelines published by the Codex Alimentarius Commission on July 4, This system will ensure the products made available through this science will go through a thorough and transparent application process before being approved for the marketplace.

Why is the New Animal Drug NAD framework the regulatory process supported by the biotechnology industry, food chain, producer groups, patient groups and consumer groups?

The NAD pathway criteria can be applied to all genetically engineered animals equitably, including those agricultural animals developed for biomedical purposes and not for food.

The NAD pathway has been used by FDA for the last decade, after scientific, regulatory, and legal experts devised this consensus-based framework to ensure coordination among all centers within FDA. This rigorous, science-based approval process has been demonstrated to be critical to consumer acceptance of the technology and the products that will result.

The NAD process is consistent with key international guidelines for food safety risk assessment for GE animals that was adopted by the Codex Alimentarius Commission on July 4, International trade has not been affected by release of the FDA Guidance. In fact, trading partners have active research programs in genetic engineering of animals. On July 4, , the member countries of the Codex Alimentarius Commission unanimously adopted international guidelines for the conduct of food safety risk assessment for genetically engineered animals.

The FDA Guidance describes a framework similar to the Codex-approved guideline for evaluating food safety risk assessment of GE animals. The international guideline was the end product of work of a task force led by Japan and Australia, which expedited the finished document due to unprecedented support from countries around the world.

The first module on Research and Development has been completed and publicly released. Additional modules that are planned for inclusion in the Guidance include Commercialization, Post-Market Monitoring, and Discontinuation - Product Recall.

Scott Gottlieb and Dr. Matthew Wheeler. Skip to main content. Share Print. What is genetic engineering? What animals are being genetically engineered? Why are animals being genetically engineered? Is a GE animal an animal clone? Benefits of Genetic Engineering What are the benefits of genetic engineering? What are the primary issues holding up realization of these benefits? Therefore, as a proactive measure, the European Commission has asked EFSA to develop comprehensive risk assessment guidelines that would be used by companies and risk assessment bodies to evaluate the possible risks for food and feed safety, the environment as well as related animal health and welfare aspects.

These will help possible future applicants when submitting their applications to EF S A. Acting on a request from the European Commission, EFSA developed comprehensive guidance for the risk assessment of food and feed derived from GM animals, including an evaluation of animal health and welfare and environmental safety.

The Authority has also developed a guidance document on the environmental risk assessment ERA of GM animals, which covers GM fish, insects, mammals and birds. Scientific developments suggest future submissions for GM animals may be made for a number of species. In some countries outside the EU, regulators are already assessing the safety of GM animal products developed for food and feed purposes. Based on these considerations, and as a proactive measure to assure consumer safety, the European Commission requested that EFSA develop comprehensive risk assessment guidance for GM animals.

They provide clear guidance to risk assessors and biotech companies. In the event of making any future application for market approval, applicants would be obliged to use. EFSA has developed two guidance documents that outline specific data requirements and the methodology for the risk assessment of GM animals. The guidance document outlines a risk assessment approach to compare GM animals and derived food and feed with their respective conventional counterparts.

The basic assumption of this type of comparative assessment is that food and feed from conventionally-bred animals have a history of safe use and therefore can serve as a baseline for the risk assessment of food and feed derived from GM animals. Important components of the risk assessment include molecular characterisation, compositional analysis and assessment of toxicity , nutritional aspects and potential allergenicity.

For example, experts will assess whether food and feed from GM animals are as nutritious to humans and animals as those from conventionally-bred animals.

The guidance document also outlines the methodology required for the comparative assessment of health and welfare aspects of GM animals. For further information on animal health and welfare aspects, see question The guidance also includes recommendations for the post-market monitoring and surveillance of food and feed derived from GM animals on a case-by case basis. Firstly, a six-stage assessment procedure should be completed.

This step-by-step process, laid down in EU legislation, should begin with identifying potential hazards and the extent of human, animal and environmental exposure to them. The next three stages are characterising the hazard and exposure and - from the combination of both - the potential risk. Finally applicants must outline risk management strategies and provide an overall risk evaluation. Secondly, applicants should address seven areas of potential risk for GM fish, insects, mammals or birds; 1 persistence and invasiveness of the GM animal, including vertical gene transfer; 2 horizontal gene transfer; 3 interactions of the GM animal with target organisms; 4 interactions of the GM animal with non-target organisms; 5 environmental impacts of the specific techniques used for the management of the GM animal; 6 impacts of the GM animal on biogeochemical processes; and 7 impacts of the GM animal on human and animal health.

The guidance also highlights a number of cross-cutting considerations that should be factored into the full ERA process. These include which non-GM animals to use as comparators, the use of appropriate surrogates if this is considered necessary, and recommendations for the assessment of potential long-term effects of GM animals as well as for the uncertainty analysis.

EFSA recognises that there are concerns about animal health and welfare related to the development of GM animals for food and feed purposes. Requirements for the assessment of animal health and welfare are integrated in both its guidance documents on GM animals. The guidance of food and feed derived from GM animals highlights the need for extensive comparative analysis of the characteristics and traits of GM animals, including physiological parameters, with those of their conventional counterparts.

It also proposes that health and welfare should be assessed at all stages of development of the GM animal.